Published in
American Society of Hematology, Blood, 23(132), p. 2456-2464, 2018
DOI: 10.1182/blood-2018-06-858613
Links
Tools
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Journal article published in 2018 by
Aurore Perrot 
,
Valerie Lauwers-Cances,
Jill Corre ,
Nelly Robillard,
Cyrille Hulin,
Marie-Lorraine Chretien,
Thomas Dejoie,
Sabrina Maheo,
Anne-Marie Stoppa,
Brigitte Pegourie,
Lionel Karlin,
Laurent Garderet,
Bertrand Arnulf,
Chantal Doyen,
Nathalie Meuleman
and other authors.
,
Valerie Lauwers-Cances,
Jill Corre ,
Nelly Robillard,
Cyrille Hulin,
Marie-Lorraine Chretien,
Thomas Dejoie,
Sabrina Maheo,
Anne-Marie Stoppa,
Brigitte Pegourie,
Lionel Karlin,
Laurent Garderet,
Bertrand Arnulf,
Chantal Doyen,
Nathalie Meuleman
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points MRD using NGS-identified patients with an excellent outcome in multiple myeloma. MRD should be assessed in every prospective trial, and is a candidate to become a primary end point.